Sildenafil linked to 69% fewer Alzheimer’s cases

Signals Inbox·August 4, 2026·Biopharma

A study of 7.23 million insurance records linked sildenafil use to 69% fewer Alzheimer’s cases over six years. That number is not clinical proof, but the signal has refused to disappear: newer databases found 30% to 54% fewer diagnoses, while a separate UK study found an 18% reduction. The tension now is simple. A cheap generic drug has enough evidence to justify a major trial, but almost no patent incentive to pay for one.

Q1What did the study actually find?

The original Nature Aging study examined insurance claims from 7.23 million people. Sildenafil users were associated with a 69% lower risk of an Alzheimer’s diagnosis over six years. The researchers also exposed patient-derived neurons to sildenafil and saw more nerve growth and lower levels of phosphorylated tau, a protein linked to Alzheimer’s.

Q2Does that mean sildenafil prevents Alzheimer’s?

Not yet. The 69% result came from medical records, not a randomized clinical trial. People taking sildenafil may differ from non-users in ways that are difficult to fully measure, including health, income, relationships and access to care. The study found a strong link, but it did not prove that the pill caused the lower risk.

Q3Did anyone reproduce the result?

Partly. Cleveland Clinic later studied two independent insurance databases and found 30% to 54% fewer Alzheimer’s diagnoses among sildenafil users. A UK study of nearly 270,000 men found a smaller 18% reduction, with the strongest association among frequent users. The exact number moves around, but several large datasets point in the same direction.

Q4So why is the evidence still controversial?

Because another major analysis found no benefit. The NIH DREAM study compared more than 13,000 patients receiving sildenafil or tadalafil with patients using another pulmonary hypertension drug. It found no significant reduction in Alzheimer’s or related dementia. That disagreement is exactly why a proper randomized trial matters.

Q5Why could sildenafil affect the brain?

Sildenafil blocks an enzyme called PDE5, which helps blood vessels relax and improves blood flow. Researchers think that could support circulation inside the brain. Laboratory work also suggests possible effects on inflammation, nerve growth and tau. These are believable mechanisms, but none proves that taking Viagra will protect a healthy person from Alzheimer’s.

Q6Why has nobody run the definitive trial?

Money is a major problem. Pfizer funded large trials when sildenafil was protected by patents for erectile dysfunction and pulmonary hypertension. Generic sildenafil is now cheap and available from many manufacturers. A long Alzheimer’s prevention trial could cost hundreds of millions of dollars, while no single company would control most of the upside if it succeeds.

Q7So what is the real signal?

The real signal is not that Viagra has cured Alzheimer’s. It is that several huge patient datasets keep finding a potentially valuable effect from an old generic drug, while the system lacks a clear owner willing to fund the final test. Sildenafil could become a major drug-repurposing win, or a famous lesson in why medical-record correlations need randomized proof. Either way, the missing trial is now the story.